{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:45:45Z","timestamp":1776231945892,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12325-023-02600-3","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:01:32Z","timestamp":1692579692000},"page":"4657-4674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication"],"prefix":"10.1007","volume":"40","author":[{"given":"Johan","family":"Dal\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Svedbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Hernlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-108X","authenticated-orcid":false,"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"6","key":"2600_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/ijr.12.61","volume":"7","author":"S Lipton","year":"2012","unstructured":"Lipton S, Deodhar A. The new ASAS classification criteria for axial and peripheral spondyloarthritis: promises and pitfalls. Int J Clin Rheumatol. 2012;7(6):675.","journal-title":"Int J Clin Rheumatol"},{"key":"2600_CR2","unstructured":"Handout on Health: Rheumatoid Arthritis. 2014, National Institute of Arthritis and Musculoskeletal and Skin Diseases."},{"issue":"6","key":"2600_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2600_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2600_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0889-857X(21)00171-X","volume":"19","author":"T Pincus","year":"1993","unstructured":"Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin N Am. 1993;19(1):123\u201351.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"2600_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/ard.2010.133371","volume":"70","author":"M Neovius","year":"2011","unstructured":"Neovius M, et al. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011;70(4):624\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2600_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard.61.10.911","volume":"61","author":"MK S\u00f6derlin","year":"2002","unstructured":"S\u00f6derlin MK, et al. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis. 2002;61(10):911\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2600_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/ard.2010.141598","volume":"70","author":"E Haglund","year":"2011","unstructured":"Haglund E, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis. 2011;70(6):943\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"2600_CR9","first-page":"S17","volume":"66","author":"S Exarchou","year":"2014","unstructured":"Exarchou S, et al. The prevalence of ankylosing spondylitis in Sweden: a Nationwide Register Study. Arthritis Rheumatol. 2014;66(Suppl):S17.","journal-title":"Arthritis Rheumatol"},{"key":"2600_CR10","unstructured":"Gjertsson I et al. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid reumatoid artrit. Svensk Reumatologisk F\u00f6rening, 2019."},{"key":"2600_CR11","unstructured":"Helena Forsblad d\u2019Elia TH, Ulf L, Agnes S, Wallman JK, Wedr\u00e9n S. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid axial spondylartrit och psoriasisartrit 2022. Svensk Reumatologisk F\u00f6rening; 2022."},{"key":"2600_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/3-7643-7438-1_2","volume-title":"TNF-alpha inhibitors","author":"SR Stevens","year":"2006","unstructured":"Stevens SR, Chang TH. History of development of TNF inhibitors. In: TNF-alpha inhibitors. Springer; 2006. p. 9\u201322."},{"issue":"4","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696998.2014.893241","volume":"17","author":"B Meissner","year":"2014","unstructured":"Meissner B, et al. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259\u201365.","journal-title":"J Med Econ"},{"key":"2600_CR14","doi-asserted-by":"crossref","unstructured":"Todoerti M et al. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology. 2018;57(Supplement_7):vii42\u2013vii53.","DOI":"10.1093\/rheumatology\/key195"},{"key":"2600_CR15","unstructured":"Aletaha D, Smolen, JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29(8):1631\u20131638."},{"key":"2600_CR16","first-page":"102","volume":"44","author":"J Fries","year":"1996","unstructured":"Fries J. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl. 1996;44:102\u20136.","journal-title":"J Rheumatol Suppl"},{"issue":"12","key":"2600_CR17","first-page":"1874","volume":"19","author":"T Pincus","year":"1992","unstructured":"Pincus T, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol. 1992;19(12):1874\u201384.","journal-title":"J Rheumatol"},{"issue":"8","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s12325-016-0371-0","volume":"33","author":"GW Cannon","year":"2016","unstructured":"Cannon GW, et al. Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther. 2016;33(8):1347\u201359.","journal-title":"Adv Ther"},{"issue":"8 Spec No.","key":"2600_CR19","first-page":"SP338","volume":"24","author":"T Gu","year":"2018","unstructured":"Gu T, et al. Cost of biologic treatment persistence or switching in rheumatoid arthritis. Am J Manag Care. 2018;24(8 Spec No.):SP338\u201345.","journal-title":"Am J Manag Care"},{"issue":"6","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.clinthera.2019.04.032","volume":"41","author":"J Vanderpoel","year":"2019","unstructured":"Vanderpoel J, et al. Health care resource utilization and costs associated with switching biologics in rheumatoid arthritis. Clin Ther. 2019;41(6):1080\u20139.","journal-title":"Clin Ther"},{"issue":"9","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/14740338.2021.1924146","volume":"20","author":"J-G Letarouilly","year":"2021","unstructured":"Letarouilly J-G, Salmon J-H, Flipo R-M. Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opin Drug Saf. 2021;20(9):1087\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"2600_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/PPA.S167508","volume":"12","author":"MJ Murage","year":"2018","unstructured":"Murage MJ, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adher. 2018;12:1483.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1403494819868042","volume":"48","author":"S L\u00f6fvendahl","year":"2020","unstructured":"L\u00f6fvendahl S, Schelin ME, J\u00f6ud A. The value of the Sk\u00e5ne Health-care Register: prospectively collected individual-level data for population-based studies. Scand J Public Health. 2020;48(1):56\u201363.","journal-title":"Scand J Public Health"},{"issue":"11","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659\u201367.","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):1\u201316.","journal-title":"BMC Public Health"},{"key":"2600_CR27","unstructured":"Welfare NBOHA. Quality declaration, statistics on pharmaceuticals for 2018. 2019."},{"key":"2600_CR28","unstructured":"Welfare NBOHA. Cause of death register. 2019. https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/alla-register\/dodsorsaksregistret\/bortfall-och-kvalitet\/."},{"issue":"7","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n J, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987\u201395.","journal-title":"Rheumatol Int"},{"issue":"12","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00296-017-3825-z","volume":"37","author":"J Dal\u00e9n","year":"2017","unstructured":"Dal\u00e9n J, et al. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatol Int. 2017;37(12):2049\u201358.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12325-021-01879-4","volume":"39","author":"J Dal\u00e9n","year":"2022","unstructured":"Dal\u00e9n J, et al. Treatment persistence in patients cycling on subcutaneous tumor necrosis factor-alpha inhibitors in inflammatory arthritis: a retrospective study. Adv Ther. 2022;39(1):244\u201355.","journal-title":"Adv Ther"},{"issue":"1","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"5","key":"2600_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"2600_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmed.2018.00039","volume":"5","author":"F Aslam","year":"2018","unstructured":"Aslam F, Khan NA. Tools for the assessment of comorbidity burden in rheumatoid arthritis. Front Med. 2018;5:39.","journal-title":"Front Med"},{"issue":"3","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","volume":"15","author":"T Hothorn","year":"2006","unstructured":"Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15(3):651\u201374.","journal-title":"J Comput Graph Stat"},{"issue":"9\u201310","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0021-9681(84)90041-9","volume":"37","author":"EF Cook","year":"1984","unstructured":"Cook EF, Goldman L. Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning analysis. J Chronic Dis. 1984;37(9\u201310):721\u201331.","journal-title":"J Chronic Dis"},{"key":"2600_CR37","unstructured":"Abdi H. Bonferroni and Sidak corrections for multiple comparisons. In: Salkind NJ, editor. Encyclopedia of measurement and statistics. Newcastle upon Tyne: Sage; 2007."},{"key":"2600_CR38","first-page":"3","volume":"8","author":"C Bonferroni","year":"1936","unstructured":"Bonferroni C. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commericiali di Firenze. 1936;8:3\u201362.","journal-title":"Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commericiali di Firenze"},{"issue":"11","key":"2600_CR39","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.200872","volume":"48","author":"E Mogard","year":"2021","unstructured":"Mogard E, et al. Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: results from the SPARTAKUS cohort. J Rheumatol. 2021;48(11):1672\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"2600_CR40","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2600_CR41","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69(11):2002\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2600_CR42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, et al. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the south swedish arthritis treatment group register. Arthritis Care Res. 2010;62(10):1362\u20139.","journal-title":"Arthritis Care Res"},{"key":"2600_CR43","doi-asserted-by":"crossref","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. In: Seminars in arthritis and rheumatism. Amsterdam: Elsevier; 2017.","DOI":"10.1016\/j.semarthrit.2017.04.005"},{"issue":"6","key":"2600_CR44","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/acr.23090","volume":"69","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res. 2017;69(6):867\u201374.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"2600_CR45","doi-asserted-by":"publisher","DOI":"10.2196\/26823","volume":"9","author":"C Barata","year":"2021","unstructured":"Barata C, et al. Predicting biologic therapy outcome of patients with spondyloarthritis: joint models for longitudinal and survival analysis. JMIR Med Inform. 2021;9(7): e26823.","journal-title":"JMIR Med Inform"},{"issue":"4","key":"2600_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/03007995.2020.1722945","volume":"36","author":"FDA Acurcio","year":"2020","unstructured":"Acurcio FDA, et al. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Curr Med Res Opin. 2020;36(4):677\u201386.","journal-title":"Curr Med Res Opin"},{"key":"2600_CR47","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","volume":"10","author":"S D'Angelo","year":"2019","unstructured":"D\u2019Angelo S, et al. Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study. Front Pharmacol. 2019;10:1497.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2600_CR48","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jbspin.2019.07.003","volume":"86","author":"F Krajewski","year":"2019","unstructured":"Krajewski F, et al. Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: a real-life multicenter study. Jt Bone Spine. 2019;86(6):761\u20137.","journal-title":"Jt Bone Spine"},{"key":"2600_CR49","unstructured":"Gonz\u00e1lez-Fern\u00e1ndez M et al. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients. Farmacia Hospitalaria. 2019."},{"key":"2600_CR50","doi-asserted-by":"crossref","unstructured":"Egeberg A et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries. In: Seminars in arthritis and rheumatism. Amsterdam: Elsevier; 2022.","DOI":"10.1016\/j.semarthrit.2022.151979"},{"issue":"5","key":"2600_CR51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40259-020-00442-x","volume":"34","author":"C-L Yu","year":"2020","unstructured":"Yu C-L, Yang C-H, Chi C-C. Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. BioDrugs. 2020;34(5):669\u201379.","journal-title":"BioDrugs"},{"issue":"Supplement 10","key":"2600_CR52","first-page":"5073","volume":"71","author":"E Hernlund","year":"2019","unstructured":"Hernlund E, et al. Decision tree analysis to identify inflammatory arthritis patient subgroups with different levels of treatment persistence with first-line subcutaneous TNF-alpha inhibitors. Arthritis Rheumatol. 2019;71(Supplement 10):5073\u20134.","journal-title":"Arthritis Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02600-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:14:56Z","timestamp":1694582096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02600-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02600-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}